Kura Oncology Stock Market Value
| KURA Stock | USD 20.95 0.13 0.62% |
| Symbol | Kura |
Kura Oncology Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.23) | Return On Assets (0.25) | Return On Equity (0.39) |
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kura Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Kura Oncology 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Kura Oncology's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Kura Oncology.
| 09/29/2023 |
| 09/23/2024 |
If you would invest 0.00 in Kura Oncology on September 29, 2023 and sell it all today you would earn a total of 0.00 from holding Kura Oncology or generate 0.0% return on investment in Kura Oncology over 360 days. Kura Oncology is related to or competes with Protagonist Therapeutics, Merus BV, Replimune, Kalvista Pharmaceuticals, Crinetics Pharmaceuticals, Viridian Therapeutics, and Monte Rosa. Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the U... More
Kura Oncology Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Kura Oncology's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Kura Oncology upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.34 | |||
| Information Ratio | (0) | |||
| Maximum Drawdown | 14.43 | |||
| Value At Risk | (3.42) | |||
| Potential Upside | 4.05 |
Kura Oncology Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kura Oncology's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Kura Oncology's standard deviation. In reality, there are many statistical measures that can use Kura Oncology historical prices to predict the future Kura Oncology's volatility.| Risk Adjusted Performance | 0.0455 | |||
| Jensen Alpha | (0.08) | |||
| Total Risk Alpha | (0.24) | |||
| Sortino Ratio | (0) | |||
| Treynor Ratio | 0.0653 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Kura Oncology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Kura Oncology Backtested Returns
At this point, Kura Oncology is very steady. Kura Oncology has Sharpe Ratio of 0.0264, which conveys that the firm had a 0.0264% return per unit of risk over the last 3 months. We have found thirty technical indicators for Kura Oncology, which you can use to evaluate the volatility of the firm. Please verify Kura Oncology's Mean Deviation of 1.87, downside deviation of 2.34, and Risk Adjusted Performance of 0.0455 to check out if the risk estimate we provide is consistent with the expected return of 0.064%. Kura Oncology has a performance score of 2 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 1.64, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Kura Oncology will likely underperform. Kura Oncology right now secures a risk of 2.42%. Please verify Kura Oncology maximum drawdown, accumulation distribution, relative strength index, as well as the relationship between the semi variance and day typical price , to decide if Kura Oncology will be following its current price movements.
Auto-correlation | -0.15 |
Insignificant reverse predictability
Kura Oncology has insignificant reverse predictability. Overlapping area represents the amount of predictability between Kura Oncology time series from 29th of September 2023 to 27th of March 2024 and 27th of March 2024 to 23rd of September 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Kura Oncology price movement. The serial correlation of -0.15 indicates that less than 15.0% of current Kura Oncology price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.15 | |
| Spearman Rank Test | -0.13 | |
| Residual Average | 0.0 | |
| Price Variance | 1.11 |
Kura Oncology lagged returns against current returns
Autocorrelation, which is Kura Oncology stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Kura Oncology's stock expected returns. We can calculate the autocorrelation of Kura Oncology returns to help us make a trade decision. For example, suppose you find that Kura Oncology has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Kura Oncology regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Kura Oncology stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Kura Oncology stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Kura Oncology stock over time.
Current vs Lagged Prices |
| Timeline |
Kura Oncology Lagged Returns
When evaluating Kura Oncology's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Kura Oncology stock have on its future price. Kura Oncology autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Kura Oncology autocorrelation shows the relationship between Kura Oncology stock current value and its past values and can show if there is a momentum factor associated with investing in Kura Oncology.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Kura Stock
When determining whether Kura Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kura Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kura Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kura Oncology Stock:Check out Kura Oncology Correlation, Kura Oncology Volatility and Kura Oncology Alpha and Beta module to complement your research on Kura Oncology. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Kura Oncology technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.